- Navigating Your Midlife Crisis: Embracing New Possibilities
- City Raccoons Showing Signs of Domestication
- Mapping the Exposome: Science Broadens Focus to Environmental Disease Triggers
- One Week Less on Social Media Linked to Better Mental Health
- Your Brain Changes in Stages as You Age, Study Finds
- Some Suicide Victims Show No Typical Warning Signs, Study Finds
- ByHeart Formula Faces Lawsuits After Babies Sickened With Botulism
- Switch to Vegan Diet Could Cut Your Greenhouse Gas Emissions in Half
- Regular Bedtime Does Wonders for Blood Pressure
- Dining Alone Could Mean Worse Nutrition for Seniors
Rural Americans Are Going Without Meds to Fight Opioid, Alcohol Addictions
Less than 9% of rural Americans who abuse both opioids and alcohol are prescribed medications to treat both disorders, new research reveals.
Naltrexone treats both opioid use disorder and alcohol use disorder. Other drugs such as buprenorphine, acamprosate or disulfiram treat one or the other.
And researchers who reviewed medical records of close to 1,900 adults who visited a rural primary care provider between October 2019 and January 2021 found that most with a dual diagnosis were being treated for only one disorder, not both.
The new study findings “call for a better understanding of these gaps as well as additional support for rural clinicians in providing pharmacological treatment,” wrote the team headed by Emily Kan of the University of California, Los Angeles.
In all, 85.3% of patients with a dual disorder were prescribed a medication for only one condition, compared to patients struggling with opioid use only (63.7%) or those battling alcohol issues only (10.3%), the study found.
Those with a dual diagnosis spent the most time on medication — about 265 days — compared to those with opioid disorder alone (220.5 days) or alcohol disorder alone (62.5 days).
Overall, 54.2% of the patients had opioid use disorder only; 37.9% alcohol use disorder only; and 7.9% had both.
“The low rates of naltrexone prescription are concerning given the current evidence of the effectiveness of extended release-naltrexone in treating both disorders,” the researchers wrote.
They said primary care practices in rural areas need help assessing and treating the disorders and also with providing telemedicine to deliver care remotely.
The findings were recently published in the Journal of Substance Use and Addiction Treatment.
More information
The U.S. Department of Health and Human Services has more more about treating drug and alcohol abuse.
SOURCE: American Psychiatric Association, news release, March 22, 2024
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.










